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Aims: Alpha-melanocyte stimulating hormone (α-MSH) is a pro-opiomelanocortin (POMC)-derived peptide
involved in different neurological functions that also exerts anti-inﬂammatory effects, including in the central
nervous system (CNS). Although inﬂammation has been implicated in seizures and epilepsy, no study has
systematically investigated whether α-MSH modiﬁes seizures. Therefore, in the current study we determined
whether α-MSH alters pentylenetetrazol (PTZ)- and pilocarpine-induced seizures.
Main methods: Adult male Swiss mice were injected with α-MSH (1.66, 5 or 15 μg/3 μL, intracerebroventricular
(i.c.v.)) or systemic (0.1, 0.3 or 1 mg/kg, intraperitoneally (i.p.)). Five to sixty minutes after the injection of the
peptide, animals were injected with PTZ (60 mg/kg, i.p.) or pilocarpine (370 mg/kg, i.p.). Latency to myoclonic
jerks and tonic–clonic seizures, number of seizure episodes, total time spent seizing and seizure intensity,
assessed by the Racine and Meurs scales were recorded. Interleukin 1 beta (IL-1β) levels in the hippocampus
were measured by a commercial enzyme-linked immunoabsorbent assay (ELISA).
Key ﬁndings: Neither intracerebroventricular (1.66, 5 or 15 μg/3 μL, i.c.v.) nor systemic (0.1, 0.3 or 1 mg/kg, i.p.)
administration ofα-MSH altered PTZ- and pilocarpine-induced seizures. IL-1β levels in the hippocampiwere not
altered by α-MSH, PTZ or pilocarpine.
Signiﬁcance: Although inﬂammation has been implicated in seizures and epilepsy and α-MSH is a potent anti-
inﬂammatory peptide, our results do not support a role for α-MSH in seizure control.© 2013 Elsevier Inc. All rights reserved.Introduction
Neurotrauma, stroke, infection, and febrile seizures are all associ-
ated with acute seizures and increased risk of developing epilepsy
(Dedeurwaerdere et al., 2012). Several lines of evidence support a
relationship between inﬂammation and epilepsy (Cremer et al.,
2009; Dedeurwaerdere et al., 2012; Perucca et al., 2007; Vezzani
et al., 2011a). Inﬂammation is triggered by molecular patterns asso-
ciated to pathogens (PAMPs) or molecular patterns associated to
damage (DAMPS) (Maroso et al., 2010). These molecules activate
the host defense system and also increase neural tissue excitability
(Matsuo et al., 2006; Rodgers et al., 2009). PAMPs and DAMPs bind
to toll-like receptors (TLR) and advanced glycation end product
receptors (RAGE), which are expressed mainly on the cell surface
of astrocytes and microglial cells in the central nervous system55 55 3220 8241.
ghts reserved.(Medzhitov, 2007). TLR have also been reported in neurons (Zhou
et al., 2009), particularly in dysplastic neurons from epileptic
patients (Zurolo et al., 2011). Interestingly, the epicortical applica-
tion of lipopolyssacaride (LPS) produces spontaneous epileptiform
discharges (Rodgers et al., 2009) and high-mobility group box-1
(HMGB1), a non-histone nuclear protein, facilitates kainate- and
bicuculine-induced seizures (Maroso et al., 2010). Moreover, it is
fairly known that activation of TLR increases microglial tumor necro-
sis factor (TNF)-α, interleukin 6 (IL-6), macrophage inﬂammatory
protein-1α (MIP-1α) and interleukin 1 beta (IL-1β) expression
(Allan et al., 2005; Dunne and O'Neill, 2003; Farooqui et al., 2007;
Li et al., 2011). In this context, several studies have described that
these pro-inﬂammatory cytokines increase seizure susceptibility
(Galic et al., 2012; Li et al., 2011; Vezzani et al., 2012).
Alpha-melanocyte stimulating hormone (α-MSH) is a thirteen
amino acid neuropeptide derived from the post-translational pro-
cessing of pro-opiomelanocortin (POMC) (Brzoska et al., 2008;
Butler, 2006; Catania et al., 2000) that binds to Gs protein-coupled
melanocortin receptors (MC-Rs) (Gantz and Fong, 2003; Mountjoy
Fig. 1. Lack of effect of α-MSH (0.1, 0.3 or 1 mg/kg, i.p., 15 min before PTZ) on PTZ-induced seizures. Latency to myoclonic jerks (A); latency to generalized tonic–clonic seizures
(B); number of seizure episodes (C); total time spent seizing (D) and Racine scale (E). Data are presented as median and interquartile range for n = 4–5 in each group.
724 F.R. Temp et al. / Life Sciences 93 (2013) 723–731et al., 1992). Three out ﬁve of MC-R subtypes described (MC1-R, MC3-R
and MC4-R) have anti-inﬂammatory role (Caruso et al., 2004; Catania
et al., 2004; Ichiyama et al., 1999; Maaser et al., 2006; Mountjoy et al.,
2003). α-MSH binding to these MC-Rs downregulates various pro-
inﬂammatory cytokines and increases the expression of the anti-
inﬂammatory cytokine IL-10 (Bhardwaj et al., 1996; Redondo et al.,
1998). α-MSH downregulates pro-inﬂammatory cytokines by
inhibiting IkB degradation. As a result, nuclear factor kB (NFkB) is
maintained complexed with IkB in the cytoplasm, and does not trigger
the transcription of target genes that encode pro-inﬂammatory cyto-
kines IL-1β, IL-6, IL-8 and TNF-α (Brzoska et al., 2008; Catania, 2008;
Catania et al., 2010; Hiscott et al., 1993; Muceniece and Dambrova,
2010).
A number of studies have suggested a role for inﬂammatory media-
tors in pentylenetetrazol (PTZ)- and pilocarpine-induced seizures
(Funck et al., 2011; Maroso et al., 2010; Oliveira et al., 2008; Rambo
et al., 2009; Vezzani et al., 2010, 2011a, 2011b), and thatα-MSH triggers
anti-inﬂammatory mechanisms in the central nervous system (CNS).
However, no study has determined whether α-MSH modify PTZ-
and pilocarpine-induced seizures. Therefore, in the current study we




Adult male Swiss mice (28 ± 3 g; n = 184), housed ten to a cage,
and maintained under controlled light and environment (12-h light/dark cycle, 24 ± 1 °C, 55% relative humidity) with free access to food
(Guabi, Santa Maria, Brazil) and water, were used. All animals were
obtained from the Animal House of the Federal University of Santa
Maria.
Behavioral tests were conducted during the light phase of the cycle
(from 9:00 a.m. to 5:00 p.m.). All experiments reported in this study
were conducted in accordance with the policies of the National Insti-
tutes of Health Guide for the Care and Use of Laboratory Animals (NIH
Publications No. 80-23), revised in 1996, and with the Institutional
and National regulations for animal research. All efforts were made to
reduce the number of animals used to a minimum, as well as to mini-
mize their suffering (Committee on Care and Use of Experimental Ani-
mal Resources of the Federal University of Santa Maria authorization
number: 008/2013).
Reagents
PTZ, pilocarpine and methylscopolamine bromide were purchased
from Sigma (St. Louis, MO, USA). α-MSH was purchased from Bachem
(CA, USA). Drugs were dissolved in sterile 0.9% NaCl or sterile
phosphate-buffered saline (PBS), pH 7.4. The murine IL-1β kit
was purchased from PreproTech (São Paulo, Brazil).
Surgical procedures
All animals were anesthetized with ketamine (100 mg/kg, intraperi-
toneally (i.p.)) and xylazine (10 mg/kg, i.p.), placed in a rodent stereotax-
ic apparatus, and were implanted with one 27-gauge guide cannula
placed1 mmabove the right lateral ventricle, at the following coordinates
Fig. 2. Lack of effect of α-MSH (0.1, 0.3 or 1 mg/kg, i.p., 30 min before PTZ) on PTZ-induced seizures. Latency to myoclonic jerks (A); latency to generalized tonic–clonic seizures
(B); number of seizure episodes (C); total time spent seizing (D) and Racine scale (E). Data are presented as median and interquartile range for n = 4 in each group.
725F.R. Temp et al. / Life Sciences 93 (2013) 723–731relative to bregma: AP 0 mm, ML 0.9 mm, V 1.6 mm from the dura
(Paxinos and Franklin, 2008). Chloramphenicol (200 mg/kg, i.p.)
(Oliveira et al., 2008) was administrated immediately before the surgical
procedure to prevent infection.
Injection procedures
The effect of α-MSH on PTZ- or pilocarpine-induced seizures was
investigated by injecting the animals with α-MSH (0.1, 0.3 or 1 mg/kg,
i.p., in those experiments in which the effect of the systemic administra-
tion of α-MSH was investigated or 1.66, 5 or 15 μg/3 μL, intracerebro-
ventricular (i.c.v.), in those experiments in which the effect of the
central administration ofα-MSHwas investigated) or respective vehicle
(sterile 0.9%NaCl, 10 mL/kg, i.p. or PBS, i.c.v.). All intracerebroventricular
injections were performed by using a Hamilton syringe and a 30-gauge
needle ﬁtted into the guide cannula. The tip of the infusion needle pro-
truded 1.0 mm beyond that of the guide cannula into the right lateral
ventricle. The needles were left in place for additional 60 s to minimize
backﬂow.
Experiment 1: effect of systemic α-MSH on PTZ-induced seizures
The effect of systemic α-MSH on PTZ-induced seizures was investi-
gated by administrating α-MSH at the doses 0.1, 0.3 or 1 mg/kg (i.p.),
or sterile 0.9% NaCl (10 mL/kg, i.p.), 15, 30 or 60 min before the
injection of PTZ (60 mg/kg, i.p.) (Funck et al., 2011). The animals were
evaluated for the appearance of behavioral seizures, as described
below. α-MSH doses and injection intervals were chosen based on a
previous study (Ichiyama et al., 1999), which has shown an anti-
inﬂammatory action of systemic α-MSH in the CNS.Experiment 2: effect of i.c.v. α-MSH on PTZ-induced seizures
Since the systemic administration of α-MSH did not alter PTZ-
induced seizures, we hypothesized that this effect could be due to its
low blood brain barrier permeability (Wilson, 1988). Therefore, the
effect of i.c.v.-administeredα-MSH on PTZ-induced seizures was inves-
tigated. α-MSH (1.66, 5 or 15 μg/3 μL) or vehicle (3 μL of PBS, pH 7.4)
were injected 15 min before PTZ (60 mg/kg, i.p.). Immediately after
PTZ injection, the animals were evaluated for the appearance of behav-
ioral seizures, as described below. Initial α-MSH doses and injection
intervals were chosen based on a previous study (Izumi et al., 1973).
Experiment 3: effect of systemic α-MSH on pilocarpine-induced seizures
Considering that α-MSH did not alter PTZ-induced seizures,
and that anticonvulsant activity depends on the chemical agent used
to induce seizures (Oliveira et al., 2008), we tested whether α-MSH
altered pilocarpine-induced seizures. Animals were injected with
methylscopolamine bromide (1 mg/kg, i.p.) (Muller et al., 2009) to at-
tenuate the peripheral cholinergic effects of pilocarpine. Fifteenminutes
after the injection of methylscopolamine, animals were injected with
saline or α-MSH (0.1, 0.3 or 1 mg/kg, i.p.). Pilocarpine (370 mg/kg,
i.p.) (Costa et al., 2012) was administered 30 min thereafter.
Experiment 4: effect of i.c.v. α-MSH on pilocarpine-induced seizures
Since the systemic administration ofα-MSH did not alter pilocarpine-
induced seizures, we decided to test whether α-MSH, administered
by the i.c.v. route, prevented seizures. Animals were injected with
methylscopolamine bromide (1 mg/kg, i.p.) to prevent the peripher-
al cholinergic effects of pilocarpine. Fifteen minutes after the injec-
tion of methylscopolamine, animals were injected with α-MSH
Fig. 3. Lack of effect of α-MSH (0.1, 0.3 or 1 mg/kg, i.p., 60 min before PTZ) on PTZ-induced seizures. Latency to myoclonic jerks (A); latency to generalized tonic–clonic seizures
(B); number of seizure episodes (C); total time spent seizing (D) and Racine scale (E). Data are presented as median and interquartile range for n = 9 in each group.
726 F.R. Temp et al. / Life Sciences 93 (2013) 723–731(1.66, 5 or 15 μg/3 μL) or vehicle (3 μL of PBS, pH 7.4). Pilocarpine
(370 mg/kg, i.p.) was administered 30 min thereafter.Experiment 5: effect of early i.c.v. α-MSH on pilocarpine-induced seizures
Considering that the half-life of α-MSH is relatively short (Ahmed
et al., 2013), we decided to decrease the time between the administra-
tion of the peptide and pilocarpine, in order to guarantee that α-MSH
would be present in the brain when pilocarpine was injected. Animals
were injected with methylscopolamine bromide (1 mg/kg, i.p.) to pre-
vent the peripheral cholinergic effects of pilocarpine. Twenty minutes
after the injection of methylscopolamine, animals were injected withFig. 4. Lack of effect of α-MSH (1.66 μg, 5 μg or 15 μg/3 μL, i.c.v., 15 min before PTZ) on PTZ-ind
(B); and number of seizure episodes (C). Data are presented as median and interquartile rangeα-MSH (15 μg/3 μL) or vehicle (3 μL of PBS, pH 7.4). Pilocarpine
(370 mg/kg, i.p.) was administered 5 min thereafter.Experiment 6: effect of early i.c.v.α-MSHand of PTZ and pilocarpine on IL-1β
levels in the hippocampus
The effect ofα-MSH, PTZ- or pilocarpine on IL-1β levels was investi-
gated by injecting the animals with α-MSH (1.66 μg/3 μL, i.c.v.) or re-
spective vehicle (sterile 0.9% NaCl, 10 mL/kg, i.p. or PBS, i.c.v.). α-MSH
or vehicle (3 μL of PBS, pH 7.4) were injected 15 min before PTZ
(60 mg/kg, i.p.). Those animals subjected to pilocarpine-induced
seizures were ﬁrst injected with methylscopolamine bromide (1 mg/uced seizures. Latency to myoclonic jerks (A); latency to generalized tonic–clonic seizure
for n = 4–10 in each group.
Fig. 5. Lack of effect ofα-MSH (0.1, 0.3 or 1 mg/kg, i.p., 30 min before pilocarpine) on pilocarpine-induced seizures. Latency to generalized tonic–clonic seizure (A); and number of seizure
episodes (B); and total time spent seizing (C) and Meurs scale (D). Data are presented as median and interquartile range for n = 6–8 in each group.
727F.R. Temp et al. / Life Sciences 93 (2013) 723–731kg, i.p.) to prevent the peripheral cholinergic effects of pilocarpine and,
15 min thereafter, they were injected with α-MSH (1.66 μg/3 μL) or
vehicle (3 μL of PBS, pH 7.4). Pilocarpine (370 mg/kg, i.p.) was
administered 30 min after α-MSH. PTZ-injected animals were
killed by decapitation 20 min after PTZ injection, and the hippo-
campi were dissected and homogenized in appropriated buffer
(PBS containing 1 mM ethylenediaminetetraacetic acid (EDTA),
0.1 mM phenylmethylsulfonyl ﬂuoride (PMSF) and bovine serum
albumin (BSA) 0.5%, pH 7.4). Samples were centrifuged at 25,000 g for
10 min and the supernatant was used to measure IL-1β levels, which
were corrected for total protein content. Protein content was measured
by the bicinchoninic acid (BCA) method (Pierce, Rockford, IL).
Seizure evaluation
After the injection of PTZ or pilocarpine, the animals were
videomonitored for 20 or 40 min, respectively, for the appearance
of seizures and the following parameters were recorded: latency to
myoclonic jerks (only for PTZ-injected animals), latency to general-
ized tonic–clonic seizures, number of seizure episodes and total
time spent seizing, according to Ferraro et al. (1999). The severity
of PTZ-induced seizures was scored by the modiﬁed Racine scale
(Luttjohann et al., 2009), as follows: (1), sudden behavioral arrest
and/or motionless staring; (2), facial jerking with muzzle or muzzle
and eye; (3), neck jerks; (4), clonic seizure in a sitting position; (5),
convulsion including clonic and/or tonic–clonic seizure while lying
on the belly and/or pure tonic seizure; and (6), convulsion including
clonic and/or tonic–clonic seizure while lying on the side and/or wildjumping. The severity of pilocarpine-induced seizures was evaluated
by the Meurs scale (Meurs et al., 2008), as follows: (0) normal, non-
epileptic activity; (1) mouth and facial movements, hyperactivity,
grooming, snifﬁng, scratching, wet dog shakes; (2) head nodding, staring,
tremor; (3) forelimb clonus, forelimb extension; (4) rearing, salivating,
tonic–clonic activity; and (5) falling, status epilepticus. Mice were
sacriﬁced 20 or 40 min after PTZ or pilocarpine injection, respectively.
Statistical analysis
Latency to myoclonic jerks and to generalized tonic–clonic seizures,
number and total time spent seizing were analyzed by Kruskal–Wallis
test followed by nonparametric Dunn's multiple comparison test be-
cause these variables did not meet ANOVA assumptions (normal distri-
bution and homoscedasticity). These data are presented as median and
interquartile range. IL1β levels were analyzed by a factorial 2 (saline or
α-MSH) × 3 (saline, PTZ or pilocarpine) ANOVA, and are presented as
mean and S.E.M. A probability of p b 0.05 was considered signiﬁcant.
Results
Experiment 1
Figs. 1, 2 and 3 show that α-MSH (0.1, 0.3 or 1 mg/kg, i.p.) injected
15, 30 or 60 min before PTZ, respectively, did not alter the latency to
PTZ-induced myoclonic jerks (A), tonic–clonic seizures (B), number of
seizure episodes (C), total time spent seizing (D) and Racine scale (E).
Fig. 6. Lack of effect ofα-MSH (1.66, 5 or 15 μg/3 μL, i.c.v., 30 min before pilocarpine) on pilocarpine-induced seizures. Latency to generalized tonic–clonic seizure (A); number of seizure
episodes (B); total time spent seizing (C) and Meurs scale (D). Data are presented as median and interquartile range for n = 8 in each group.
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Racine score.Experiment 2
Fig. 4 shows thatα-MSH (1.66, 5 or 15 μg/3 μL, i.c.v.), injected 15 min
before PTZ, did not alter the latency to PTZ-induced myoclonic jerks
(A), tonic–clonic seizures (B), number of seizure episodes (C), total time
spent seizing (D) and seizure severity, as assessed by themodiﬁed Racine
scale (E).Experiment 3
Fig. 5 shows that α-MSH (0.1, 0.3 or 1 mg/kg, i.p.), injected 30 min
before pilocarpine, did not alter the latency to pilocarpine-induced
tonic–clonic seizures (A), number of seizure episodes (B), total time
spent seizing (C) and Meurs scale (D).α-MSH also did not alter seizure
severity, as assessed by the modiﬁed Meurs score.Experiment 4
Fig. 6 shows that α-MSH (1.66, 5 or 15 μg/3 μL, i.c.v.), injected
30 min before pilocarpine (370 mg/kg, i.p.), did not alter the latency
to pilocarpine-induced tonic–clonic seizures (A), the number of seizure
episodes (B), total time spent seizing (C) and Meurs score (D).Experiment 5
Fig. 7 shows that α-MSH (15 μg/3 μL, i.c.v.), injected 5 min before
pilocarpine (370 mg/kg, i.p.), did not alter the latency to pilocarpine-
induced tonic–clonic seizures (A), the number of seizure episodes
(B), total time spent seizing (C) and Meurs score (D).
Experiment 6
Fig. 8 shows that IL-1β levels in the hippocampi were not altered by
α-MSH (1.66 μg/3 μL, i.c.v.), PTZ (60 mg/kg, i.p.) or pilocarpine
(370 mg/kg, i.p.). Notwithstanding, a naïve group (control data, not
included in the factorial ANOVA) presented hippocampal IL-1β levels
approximately 45% lower than injected animals, indicating that the sur-
gical procedure and cannula implantation, per se, increased the hippo-
campal IL-1β content. Whole data analysis (including the naïve group)
by a single factor analysis revealed a signiﬁcant effect F(6,22) = 3.71;
p = 0.011. Accordingly, post hoc analysis (Student–Newman–Keuls
multiple comparisons test) revealed that the mean of the naïve group
differed from all other groups.
Discussion
The current study showed that neither systemic nor intracerebro-
ventricular administration of α-MSH attenuated seizures, regardless of
α-MSHdose, timebetween peptide and convulsant injection, or convul-
sant agent used.
Fig. 7. Lack of effect of α-MSH (15 μg/3 μL, i.c.v., 5 min before pilocarpine) on pilocarpine-induced seizures. Latency to generalized tonic–clonic seizure (A); number of seizure episodes
(B); total time spent seizing (C) and Meurs scale (D). Data are presented as median and interquartile range for n = 6 in each group.
Fig. 8. Lack of effect of α-MSH (1.66 μg/3 μL, i.c.v.), PTZ (60 mg/kg, i.p.) or pilocarpine
(370 mg/kg, i.p.) on IL-1β levels in the hippocampus. All groups differ from naive
(SNK test) for a p b 0.05.
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fragments on seizures. The i.c.v. administration of the peptide ORG-
2766, a 4–9 fragment of adrenocorticotropic hormone (ACTH) and
desacetyl α-MSH sequences, decreases seizures in electrically kindled
mice (Goldman and Berman, 1984). Notwithstanding, ORG-2766 does
not displace labeledα-MSH in cell preparations, even at concentrations
within the millimolar range (Schioth et al., 1995), suggesting that it
does not interact withα-MSHbinding sites. Therefore, it seems unlikely
that α-MSH receptors are involved in the anticonvulsant effect of ORG-
2766 in mice, as initially thought. Moreover, ORG-2766 did not signiﬁ-
cantly alter seizure frequency of four children with intractable seizures
(Pentella et al., 1982).Willig and Lagenstein (1980) studied the effect of
the 4–10 ACTH fragment (which corresponds to the desacetyl 4–10 α-
MSH fragment) on seizure frequency of seven epileptic children
and, similar to Pentella et al. (1982), did not ﬁnd any improvement
in seizure frequency or in the EEG pattern of the studied patients.
On the other hand, Croiset and De Wied (1992), have found
that whereas ACTH(1–39), ACTH(1–24), ACTH(1–18), ACTH(1–16)
and ACTH(18–39) were not active, subcutaneous pretreatment with
smaller ACTH-like fragments, such as ACTH(4–9), ACTH(4–10),
ACTH(4–10)(7D-Phe), ACTH(7–16), and ORG-2766, reduced the sever-
ity of pilocarpine (2.4 mg/2 μL, i.c.v.)-induced seizures. The authors
have argued that anti-epileptic activity appeared to reside in the
sequence 1–16 and, more speciﬁcally, in the sequences 4–7 and 7–16,
of the ACTH molecule.
Plotnikoff and Kastin (1976), have suggested that α-MSH (0.01–
1 mg/kg, i.p.) by itself decreases the percentage of mice that present
730 F.R. Temp et al. / Life Sciences 93 (2013) 723–731audiogenic-evoked seizures. Notwithstanding, the differences between
groups reported in that study were not statistically signiﬁcant. On the
other hand, Izumi et al. (1973) have shown that α-MSH (10 μg, i.c.v.)
decreases the latency to ouabain-elicited seizures in rats, suggesting
that this peptide may facilitate seizures. However, the large injected
volume (50 μL) into the left lateral ventricle may have added a
confounding factor (increased cranial pressure and expanded extra-
cellular volume, for instance), and contributed for the observed effects
(Routtenberg, 1972).
Our ﬁrst set of experiments demonstrated that systemically-
administered α-MSH does not alter PTZ-induced seizures. Regarding
this point, it is worth mentioning that, until the present moment,
neither active nor facilitated transport has been reported for any α-
MSH fragment or analog in the blood–brain barrier (BBB). Current
evidence suggests that diffusion of the peptide across the BBB is poor
in mice, similar to other water-soluble macromolecules, such as inulin
(Wilson, 1988). Notwithstanding, systemicα-MSH suppresses fever in-
duced LPS (25 μg/kg, i.p.) via central melanocortin receptors regardless
of suppression of corticosterone and IL-6 release (Huang et al., 1998),
suggesting that despite its low BBB permeability, low systemic doses
of α-MSH alter central functions.
The limited penetration of the peptide into the CNS (Rapoport et al.,
1980; Wilson, 1988) in mice motivated the experiment that investigat-
edwhether i.c.v. injectedα-MSHdecreased PTZ-induced seizures. How-
ever, α-MSH (1.66, 5 or 15 μg/3 μL, i.c.v.), did not prevent or attenuate
PTZ-induced seizures measured as latency to myoclonic jerks and
tonic–clonic seizures, and number of seizure episodes (Fig. 4A–C).
Although PTZ-induced seizures have been associated with variable
degree of BBB disruption (Lorenzo et al., 1975), and inhibited by select-
ed anti-inﬂammatory agents (Oliveira et al., 2008), pilocarpine-induced
status epilepticus have been reported to highly depend on increased
BBB permeability (Marchi et al., 2007) and on early peripheral
(Marchi et al., 2009) and central inﬂammation (Fabene et al., 2010).
Therefore, considering that an anti-inﬂammatory role for α-MSH
has been demonstrated in both periphery (Hiltz and Lipton, 1989) and
central nervous system (Lasaga et al., 2008; Muceniece and Dambrova,
2010), we hypothesized that α-MSH would probably be more effective
in an experimental model of status epilepticus that depends on periph-
eral and central inﬂammation, the pilocarpine model. However, the
systemic administration of α-MSH, at doses recognized to decrease
peripheral and central inﬂammatory markers (Ichiyama et al., 1999;
Rajora et al., 1997), did not attenuate pilocarpine-induced seizures, fur-
ther suggesting a lack of anticonvulsant effect ofα-MSH. In this respect,
it is interesting that a single large dose of systemicα-MSH inhibits fever,
but not other aspects of the LPS-induced acute phase response (Martin
and Lipton, 1990). Therefore, based on these ﬁndings, one might also
propose that the inhibitory effect of α-MSH on the inﬂammatory
response may not quantitative or qualitatively comprehend those
involved in thedevelopment of pilocarpine-induced seizures. Regarding
this point it is particularly interesting that operatedmice presented high
levels of IL-1β compared with the naïve group, regardless of the phar-
macological treatment (Fig. 8). Therefore, it is possible that α-MSH is
not able to modify an already established inﬂammatory response,
thoughα-MSH (i.c.v.) has been reported to decrease IL1β-induced acti-
vation of the hypothalamic–pituitary–adrenal (HPA) axis (Cragnolini
et al., 2004).
All mice injected i.c.v. with 1.66, 5 or 15 μg of α-MSH exhibited un-
usual behaviors, such as hindlimband forelimb stretchings and yawning
(supplementary content), whereas those mice injected with α-MSH by
the i.p. route did not. Such a behavioral repertoire has been previously
shown in animals subjected to intracerebral injection of α-MSH, but
not after intravenous injections of the peptide (Bertolini et al., 1988;
Ferrari et al., 1963). The observation that the i.c.v. injection of the
peptide induces a known typical behavioral repertoire indicates that
animals received biologically active doses of the peptide, and rule out
the possibility that insufﬁcient amounts of α-MSH or other factorother than the lack of anticonvulsant action of the neuropeptide
underlie the currently reported lack of effect of α-MSH. At last, it is
worth mentioning that control unpublished results show that both
PTZ- and pilocarpine-induced seizures are attenuated by phenobarbital
(20 mg/kg, per oral route (p.o.)), conﬁrming the vast literature showing
that PTZ- and pilocarpine-induced seizures are sensitive to known
anticonvulsants, and the suitability of these animal models for investi-
gating drugswith anticonvulsant activity (Moshé et al., 2006). Notwith-
standing, we do not rule out an anticonvulsant effect ofα-MSH in other
models.
In summary, our data support that either systemic or
intracerebroventricularly-administered α-MSH does not alter PTZ-
or pilocarpine induced seizures.
Conclusion
The current results do not imply a protective role for α-MSH against
PTZ- and pilocarpine-induced seizures.
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